Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 1:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Spontaneous Urticaria
Interventions
AK006 IV
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
9
States / cities
Birmingham, Alabama • Bakersfield, California • Upland, California + 6 more
Conditions
Urticaria
Interventions
GDC-0853
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 7 more
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
11
States / cities
Bakersfield, California • San Diego, California • Miami, Florida + 8 more
Conditions
Urticaria
Interventions
GDC-0853, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 10 more
Conditions
Chronic Spontaneous Urticaria
Interventions
barzolvolimab, Matching placebo
Biological
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
63
States / cities
Cullman, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 47 more
Conditions
Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Interventions
124I AT-01
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Chronic Spontaneous Urticaria
Interventions
Benralizumab, Placebo and Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more
Conditions
Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions
EDP-978, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Chronic Idiopathic Urticaria
Interventions
benralizumab, placebo
Biological
Lead sponsor
Jonathan A. Bernstein, MD
Other
Eligibility
19 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
Interventions
KPL-716, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more
Completed Early Phase 1 Interventional Results available

Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

NCT03494881
Conditions
Chronic Spontaneous Urticaria
Interventions
Nucala
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Chronic Inducible Urticaria
Interventions
Remibrutinib, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 21 more
Conditions
Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 18 more
Conditions
Urticaria, Patch Testing, Dermatitis, Allergy, Contact Sensitization
Interventions
Patch Testing
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Chronic Spontaneous Urticaria
Interventions
Briquilimab, Placebo
Drug · Other
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
Conditions
Chronic Idiopathic Urticaria
Interventions
Omalizumab Injection, Xolair Prefilled Syringe
Drug
Lead sponsor
Kashiv BioSciences, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more
Conditions
Chronic Idiopathic Urticaria
Interventions
Omalizumab, Placebo, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Scottsdale, Arizona • Mission Viejo, California • Napa, California + 35 more
Conditions
Chronic Spontaneous Urticaria
Interventions
EVO756, Placebo control
Drug
Lead sponsor
Evommune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Fremont, California + 38 more
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Etanercept for the Treatment of Chronic Urticaria

NCT01030120
Conditions
Chronic Idiopathic Urticaria
Interventions
etanercept, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Chronic Spontaneous Urticaria
Interventions
QGE031, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more
Conditions
Allergic Rhinitis, Chronic Urticaria
Interventions
Levocetirizine 1.25 mg, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
6 Months to 11 Months
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more
Conditions
Chronic Spontaneous Urticaria
Interventions
Dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 11 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Coral Gables, Florida • Boise, Idaho • St Louis, Missouri + 6 more
Conditions
Lower Back Pain Chronic
Interventions
peripheral magnetic stimulation, Home exercise
Device · Behavioral
Lead sponsor
Joe X. Zhang
Federal
Eligibility
18 Years to 64 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Edwards Air Force Base, California
Conditions
Chronic Spontaneous Urticaria
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Kirksville, Missouri